STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Nov. 30, 2020

Equity [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended				Nine Months Ended
	November 30,				November 30,
	2020		2019		2020		2019
Cost of revenues	$	184	$	221	$	562	$	558
Research and development		798		723		2,167		1,769
Selling and marketing		770		1,058		2,035		2,709
General and administrative		1,278		1,650		3,860		4,342
Restructuring		-		-		875		-
	$	3,030	$	3,652	$	9,499	$	9,378

Summary of Stock Option Activity

Changes in our outstanding stock options during the nine months ended November 30, 2020 were as follows (options in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 29, 2020		1,071		$	14.65		6.2
Granted		—			—
Exercised		(70	)		4.03
Forfeited or expired		(152	)		17.52
Outstanding at November 30, 2020		849		$	15.02		5.8	$	408
Exercisable at November 30, 2020		578		$	14.37		4.8	$	408

Summary of Restricted Stock Shares (RSU's), and Performance Stock Units (PSU's) Activity

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the nine months ended November 30, 2020 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 29, 2020		2,215		$	14.47
Granted		1,856			7.94
Vested		(636	)		15.07		207
Forfeited		(277	)		12.44
Outstanding at November 30, 2020		3,158		$	10.69